Regulus Therapeutics CEO Kleanthis Xanthopoulos is abruptly stepping down from the top spot as the company awaits key clinical trial results for its in-development hepatitis C treatment, spooking investors and sending the biotech’s shares sharply downward.

…read more

Source: Regulus tanks on CEO’s exit as investors fear a bad omen


0 No comments